Adaptive gets expanded FDA clearance for ClonoSEQ assay

Create PDF

“The FDA clearance of ClonoSEQ in CLL represents a significant advancement for patients with CLL,” Lance Baldo, chief medical officer of Adaptive Biotechnologies, said in a press statement. “We believe this first-time clearance for ClonoSEQ in blood will be advantageous for both providers and patients. Given the risks that COVID-19 poses for cancer patients, we are proud to be collaborating with two best-in-class service providers to offer ClonoSEQ patients flexible and safe options for blood sample collection outside of a hospital or clinic.”